IGF1R and neoplasm: Cixutumumab, also known as IMC-A12, is a potent, highly selective, fully human IgG1 monoclonal blocking antibody with dual, subnanomolar inhibitory activity (IC50 = 0.6–1 nM) against IGF-1R homodimers as well as heterodimeric insulin receptor /IGF-1R in tumor cells (Figure 1) [65, 66].